Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
6.08 USD | -1.30% | +1.33% | -56.38% |
Financials (USD)
Sales 2024 * | 18.59M | Sales 2025 * | 12.89M | Capitalization | 510M |
---|---|---|---|---|---|
Net income 2024 * | -223M | Net income 2025 * | -247M | EV / Sales 2024 * | 2.61 x |
Net cash position 2024 * | 462M | Net cash position 2025 * | 205M | EV / Sales 2025 * | 23.7 x |
P/E ratio 2024 * |
-2.08
x | P/E ratio 2025 * |
-1.97
x | Employees | 255 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 92.38% |
Latest transcript on Verve Therapeutics, Inc.
1 day | -1.30% | ||
1 week | +1.33% | ||
Current month | +1.16% | ||
1 month | -27.62% | ||
3 months | -48.52% | ||
6 months | -63.70% | ||
Current year | -56.38% |
Managers | Title | Age | Since |
---|---|---|---|
Sekar Kathiresan
FOU | Founder | 52 | 17-12-31 |
Allison Dorval
DFI | Director of Finance/CFO | 48 | 21-11-28 |
Andrew Ashe
PSD | President | 57 | 18-07-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Burt Adelman
FOU | Founder | 71 | 17-12-31 |
Lonnel Coats
BRD | Director/Board Member | 58 | 22-08-07 |
Michael MacLean
BRD | Director/Board Member | 58 | 21-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
4.13% | 2 M€ | -25.75% | ||
3.54% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 6.08 | -1.30% | 1,464,270 |
24-05-07 | 6.16 | -3.90% | 888,521 |
24-05-06 | 6.41 | 0.00% | 812,274 |
24-05-03 | 6.41 | +4.23% | 1,394,807 |
24-05-02 | 6.15 | +2.50% | 949,617 |
Delayed Quote Nasdaq, May 08, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-56.38% | 510M | |
+22.56% | 46.71B | |
-1.51% | 41.52B | |
+48.83% | 41.8B | |
-3.42% | 29.55B | |
+10.13% | 25.78B | |
-20.44% | 19.26B | |
+26.45% | 11.98B | |
-0.14% | 12.14B | |
-0.47% | 12.08B |
- Stock Market
- Equities
- VERV Stock